bit.bio Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
116
- Latest Deal Type
-
Series D
- Latest Deal Amount
-
$25M
- Investors
-
30
bit.bio General Information
Description
Developer of a synthetic biology platform designed to accelerate research, drug discovery, and cell therapy development through engineered human cell production. The company offers induced pluripotent stem cell-derived cells, proprietary gene-targeting technology, datasets, and research services, enabling biotechnology companies, pharmaceutical companies, and research institutions to improve disease modeling, train AI models, reduce development costs, and expand cell therapy applications.
Contact Information
Website
www.bit.bioCorporate Office
- The Dorothy Hodgkin Building
- Babraham Research Campus
- Cambridge CB22 3FH
- England, United Kingdom
Corporate Office
- The Dorothy Hodgkin Building
- Babraham Research Campus
- Cambridge CB22 3FH
- England, United Kingdom
bit.bio Timeline
bit.bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Later Stage VC (Series D) | 04-Nov-2026 | $25M | Completed | Generating Revenue | ||
| 11. Secondary Transaction - Private | 01-Apr-2026 | Completed | Generating Revenue | |||
| 10. Later Stage VC (Series C) | 09-Jan-2026 | Completed | Generating Revenue | |||
| 9. Accelerator/Incubator | 19-Mar-2024 | Completed | Generating Revenue | |||
| 8. Later Stage VC | 01-Nov-2023 | Completed | Generating Revenue | |||
| 7. Later Stage VC | 31-Dec-2021 | Completed | Generating Revenue | |||
| 6. Early Stage VC (Series A) | 28-Feb-2020 | Completed | Generating Revenue | |||
| 5. Grant | 01-Dec-2019 | Completed | Generating Revenue | |||
| 4. Seed Round | 27-Mar-2019 | $4.28M | $4.68M | Completed | Generating Revenue | |
| 3. Seed Round | 16-Nov-2017 | $395K | $395K | Completed | Generating Revenue |
bit.bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-2 | ||||||||
| Series B-1 | ||||||||
| Series A | ||||||||
| Series A | ||||||||
| Seed | 496,991 | $0.000001 | $8.03 | $8.03 | 1x | $8.03 | 10.88% | |
| Ordinary | 280,010 | $0.000001 | $1.42 | $1.42 | 1x | $1.42 | 6.13% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
bit.bio Comparisons
Industry
Financing
Details
bit.bio Competitors (56)
One of bit.bio’s 56 competitors is GC Therapeutics, a Venture Capital-Backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| GC Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| ReproCELL | Formerly VC-backed | Yokohama, Japan | ||||
| AllCells | Private Equity-Backed | Alameda, CA | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA | ||||
| ArsenalBio | Venture Capital-Backed | South San Francisco, CA |
bit.bio Patents
bit.bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026202524-A1 | Controllable transcription | Pending | 27-Mar-2025 | ||
| WO-2026167379-A1 | Method of generating glutamatergic neurons | Pending | 10-Feb-2025 | ||
| WO-2026132788-A2 | Method of generating lineage-restricted cells | Pending | 20-Dec-2024 | ||
| WO-2026132788-A3 | Method of generating lineage-restricted cells | Pending | 20-Dec-2024 | ||
| WO-2026132775-A1 | Controllable transcription | Pending | 17-Dec-2024 | C07K14/4702 |
bit.bio Signals
bit.bio Investors (30)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| M&G | Asset Manager | Minority | ||
| Tech Nation Group | Accelerator/Incubator | |||
| Cambridge Enterprise Ventures | Venture Capital | Minority | ||
| Charles River Laboratories International | Corporation | Minority | ||
| Dynamk Capital | Venture Capital | Minority |
bit.bio Investments (1)
bit.bio’s most recent deal was a Joint Venture with Bit Bio Discovery. The deal was made on 09-Sep-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Bit Bio Discovery | 09-Sep-2020 | Joint Venture | Biotechnology |
bit.bio FAQs
-
When was bit.bio founded?
bit.bio was founded in 2016.
-
Where is bit.bio headquartered?
bit.bio is headquartered in Cambridge, United Kingdom.
-
What is the size of bit.bio?
bit.bio has 116 total employees.
-
What industry is bit.bio in?
bit.bio’s primary industry is Biotechnology.
-
Is bit.bio a private or public company?
bit.bio is a Private company.
-
What is bit.bio’s current revenue?
The current revenue for bit.bio is .
-
How much funding has bit.bio raised over time?
bit.bio has raised $259M.
-
Who are bit.bio’s investors?
M&G, Tech Nation Group, Cambridge Enterprise Ventures, Charles River Laboratories International, and Dynamk Capital are 5 of 30 investors who have invested in bit.bio.
-
Who are bit.bio’s competitors?
GC Therapeutics, ReproCELL, AllCells, Genetix Biotherapeutics, and ArsenalBio are some of the 56 competitors of bit.bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process